The next generation of pharma.

BIOMIND LABS ANNOUNCES FILING OF CONTINUOUS DISCLOSURE DOCUMENTS AND APPOINTMENT OF SCOTT ACKERMAN TO THE BOARD

TORONTO, CANADA – November 18, 2025 - Biomind Labs Inc. ("**Biomind**" or the "**Company**") (CBOE: BMND) (OTC PINK: BMNDF) (FRA: 3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, announces that it has filed the following continuous disclosure documents under its profile on SEDAR+ (www.sedarplus.ca):

- Amended & restated management's discussion & analysis and officers' certificates for the year ended December 31, 2024;
- Amended & restated management's discussion & analysis and officers' certificates for the three months ended March 31, 2025;
- Amended & restated management's discussion & analysis and officers' certificates for the six months ended June 30, 2025; and
- Interim unaudited financial statements, management's discussion & analysis and officers' certificates for the nine months ended September 30, 2025.

The amended & restated management's discussion & analysis were prepared and filed based on a corrective disclosure request by staff of the Ontario Securities Commission (the "**Commission**") in connection with a staff review.

The amendments to the management's discussion & analysis include; enhancements and clarifications to the Company's current status of its business operations and drug candidate programs, the provision of more detail relating to the results of operations of the current periods as compared to comparative periods, including explanations to quantify material contributing factors to the period over period variances, and in the management's discussion & analysis for the year ended December 31, 2024, the addition of audit committee and corporate governance disclosure.

The Company also announces that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.

The Company is currently subject to a cease trade order issued on April 4, 2025 (the "**FFCTO**") against the Company by the Commission for failure to file audited financial statements for the year ended December 31, 2024, corresponding management's discussion and analysis and officers' certificates, and the annual information form for the year ended December 31, 2024. While the FFCTO remained in effect, the interim unaudited financial statements, management's discussion & analysis and officers certificates for the three-month period ending March 31, 2025, Form 51-102F6 Statement of Executive Compensation, the interim unaudited financial statements, management's discussion & analysis and officers certificates for the six-month period ending June 30, 2025, and the interim unaudited financial statements, management's discussion & analysis and officers certificates for the nine-month period ending September 30, 2025, came due on May 15, 2025, May 20, 2025, August 14, 2025, and November 14, 2025, respectively.

The next generation of pharma.

The annual financial statements, amended & restated management's discussion and analysis and officers certificates for the fiscal year ended December 31, 2024, the interim unaudited financial statements, amended & restated management's discussion and analysis and officers certificates for the three-month period ending March 31, 2025 and the six-month period ending June 30, 2025, the annual information form for the year ended December 31, 2024, Form 51-102F6 – Statement of Executive Compensation, and the interim unaudited financial statements, management's discussion & analysis and officers certificates for the nine-month period ending September 30, 2025, have been filed by the Company and are available on SEDAR+ at www.sedarplus.ca.

About Biomind Labs Inc.
Biomind Labs Inc. is a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems for psychiatric and neurological conditions that affect the Central Nervous System. Leveraging translational neuroscience and formulation science, Biomind aims to optimize the pharmacological profile of key endogenous and naturally derived molecules to address unmet needs in the CNS therapeutics. The Company is committed to rigorous clinical validation and patient-centric innovation.

For more information, please contact:
Biomind Labs Inc.
Alejandro Antalich
Chief Executive Officer
Email: future@biomindlabs.com
Tel: + 598 97 663166

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute "forward-looking information" ("forward-looking information") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this document include, among others, statements relating to the Company's ability to scientifically harness the medicinal power of certain molecules to treat patients suffering from neurological and psychiatric disorders, future research and development in various therapeutic areas, the anticipated results and potential of the Company's future trials, the ability to obtain regulatory approvals, the marketability of the Company's products, ability to source raw materials in the formulation of products, ability to raise capital, and the Company's plan to engineer proprietary drug development platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company's business and results of operations; (d) fluctuations in securities markets; (e) adverse changes in the public perception of tryptamine-based treatments and phenethylamine-based therapies; (f) fluctuations in general macroeconomic conditions; (g) expectations regarding the size of the targeted market; (h) the ability of the Company to successfully achieve its business objectives; (i) plans for growth; (j) political, social and environmental uncertainties; (k) employee relations; (l) the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and (m) the risk factors set out in the Company's annual information

form for the year ended December 31, 2024, which is available under the Company's Issuer profile on SEDAR+ at www.sedarplus.ca. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The United States Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments or phenethylamine-based therapies. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of tryptamines, tryptamine derivatives or phenethylamines, phenethylamine derivatives can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in commercial clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The Cboe Canada Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.